中證網訊（記者(zhe) 黃靈(ling)靈(ling)）深交(jiao)所(suo)3月(yue)1日(ri)(ri)發布對海(hai)南(nan)海(hai)藥及(ji)公(gong)(gong)司(si)(si)董秘李日(ri)(ri)萌給予通報批評處分(fen)的(de)(de)(de)決定(ding)。經(jing)查明，海(hai)南(nan)海(hai)藥于2月(yue)14日(ri)(ri)晚間(jian)直通披(pi)露(lu)的(de)(de)(de)《關于抗病(bing)毒藥物(wu)研(yan)(yan)制取得進展的(de)(de)(de)公(gong)(gong)告》稱，公(gong)(gong)司(si)(si)“通過與國內外合(he)作伙伴(ban)的(de)(de)(de)緊密合(he)作，已(yi)(yi)經(jing)完(wan)成(cheng)瑞德(de)西韋原料藥及(ji)制劑(ji)工藝研(yan)(yan)發”“公(gong)(gong)司(si)(si)已(yi)(yi)經(jing)完(wan)成(cheng)瑞德(de)西韋制劑(ji)的(de)(de)(de)第(di)一批生(sheng)產，并已(yi)(yi)具(ju)備年產350 萬支(zhi)的(de)(de)(de)規(gui)模化(hua)生(sheng)產能(neng)(neng)力”等(deng)消(xiao)息(xi)。但公(gong)(gong)司(si)(si)在(zai)公(gong)(gong)告中未對抗病(bing)毒藥物(wu)研(yan)(yan)制合(he)作伙伴(ban)的(de)(de)(de)合(he)作模式、各方權利義務(wu)等(deng)重要信(xin)(xin)息(xi)進行(xing)披(pi)露(lu)，而上述信(xin)(xin)息(xi)對公(gong)(gong)司(si)(si)股票及(ji)其(qi)衍生(sheng)品種交(jiao)易(yi)價格可(ke)能(neng)(neng)產生(sheng)較大影響，公(gong)(gong)司(si)(si)信(xin)(xin)息(xi)披(pi)露(lu)不完(wan)整(zheng)，構(gou)成(cheng)對投資(zi)者(zhe)投資(zi)決策的(de)(de)(de)誤(wu)導性陳(chen)述。